RT Journal Article SR Electronic T1 177Lu-PSMA Therapy JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 205 OP 212 DO 10.2967/jnmt.122.263814 VO 50 IS 3 A1 Ephraim E. Parent A1 Bital Savir-Baruch A1 Isis W. Gayed A1 Frankis Almaguel A1 Bennett B. Chin A1 Austin R. Pantel A1 Evan Armstrong A1 Amanda Morley A1 Robin C. Ippisch A1 Robert R. Flavell YR 2022 UL http://tech.snmjournals.org/content/50/3/205.abstract AB Radiopharmaceutical therapy using 177Lu-prostate-specific membrane antigen (PSMA) is an effective prostate cancer treatment that was recently approved by the U.S. Food and Drug Administration. This method leverages the success of PSMA-targeted PET imaging, enabling delivery of targeted radiopharmaceutical therapy; has demonstrated a clear benefit in large prospective clinical trials; and promises to become part of the standard armamentarium of treatment for patients with prostate cancer. This review highlights the evidence supporting the use of this agent, along with important areas under investigation. Practical information on technology aspects, dose administration, nursing, and the role of the treating physician is highlighted. Overall, 177Lu-PSMA treatment requires close collaboration among referring physicians, nuclear medicine technologists, radiopharmacists, and nurses to streamline patient care.